CA2939562C - Parenteral compositions of celecoxib - Google Patents

Parenteral compositions of celecoxib Download PDF

Info

Publication number
CA2939562C
CA2939562C CA2939562A CA2939562A CA2939562C CA 2939562 C CA2939562 C CA 2939562C CA 2939562 A CA2939562 A CA 2939562A CA 2939562 A CA2939562 A CA 2939562A CA 2939562 C CA2939562 C CA 2939562C
Authority
CA
Canada
Prior art keywords
celecoxib
oil
emulsion
less
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2939562A
Other languages
English (en)
French (fr)
Other versions
CA2939562A1 (en
Inventor
Franklin Okumu
Jan-Jon Chu
Julie Ann Webb
Rafael Anthony Sabino
Andrew Xian Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Latitude Pharmaceuticals Inc
Original Assignee
Latitude Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latitude Pharmaceuticals Inc filed Critical Latitude Pharmaceuticals Inc
Publication of CA2939562A1 publication Critical patent/CA2939562A1/en
Application granted granted Critical
Publication of CA2939562C publication Critical patent/CA2939562C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
CA2939562A 2014-02-11 2015-02-11 Parenteral compositions of celecoxib Active CA2939562C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461938338P 2014-02-11 2014-02-11
US61/938,338 2014-02-11
PCT/US2015/015379 WO2015123272A1 (en) 2014-02-11 2015-02-11 Parenteral compositions of celecoxib

Publications (2)

Publication Number Publication Date
CA2939562A1 CA2939562A1 (en) 2015-08-20
CA2939562C true CA2939562C (en) 2023-02-14

Family

ID=52589802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2939562A Active CA2939562C (en) 2014-02-11 2015-02-11 Parenteral compositions of celecoxib

Country Status (8)

Country Link
US (2) US9446056B2 (de)
EP (1) EP3104840B8 (de)
JP (1) JP2017505349A (de)
CN (1) CN108472253A (de)
AU (1) AU2015217309A1 (de)
CA (1) CA2939562C (de)
RU (1) RU2016136430A (de)
WO (1) WO2015123272A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038013B1 (ru) * 2015-05-28 2021-06-23 Др. Редди'С Лабораториз Лтд. Пероральная композиция целекоксиба для лечения боли
CN105343002B (zh) * 2015-11-27 2019-07-26 济南康和医药科技有限公司 一种依托考昔口服微乳制剂及其制备方法
CN105560181A (zh) * 2016-01-28 2016-05-11 湖南省畜牧兽医研究所 一种痢菌净可注射缓释纳米乳制剂及其制备方法
EP3463340A2 (de) 2016-05-27 2019-04-10 Dr. Reddy's Laboratories Ltd. Orale zusammensetzung von celecoxib zur schmerzbehandlung
US11813355B2 (en) * 2016-12-30 2023-11-14 Universidad De Chile Curcumin-loaded nanoemulsions, method of manufacture, and method of preventive treatment using the same
CN111867562B (zh) * 2018-03-07 2023-07-07 陈献 不溶性药物的水性制剂
DE102018205493A1 (de) * 2018-04-11 2019-10-17 B. Braun Melsungen Ag Verfahren zur Herstellung einer O/W-Emulsion, O/W-Emulsion und Anlage zur Herstellung einer O/W-Emulsion
US20230073803A1 (en) * 2019-12-16 2023-03-09 Themis Medicare Limited Pharmaceutical composition of cyclooxygenase - 2 inhibitors
CN113041222B (zh) * 2021-03-23 2022-10-25 北京诺康达医药科技股份有限公司 一种注射乳剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4015108A1 (de) 1990-05-11 1991-11-14 Leopold Pharma Gmbh Stabile emulsion zur applikation pharmakologisch aktiver wirkstoffe
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
SK20012000A3 (sk) * 1998-06-29 2001-08-06 Pharmaceuticals Applications Asociates, Llc Transdermálny prostriedok na zmiernenie bolesti
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6589557B2 (en) 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
CA2431606C (en) * 2000-12-19 2011-07-19 The Board Of Regents Of The University Of Texas System Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
WO2003035063A1 (en) 2001-10-25 2003-05-01 Dinesh Shantilal Patel Novel preparation of selective cyclooxygenase ii inhibitors
CA2537029C (en) 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
US20070036831A1 (en) * 2005-08-09 2007-02-15 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US20110021592A1 (en) * 2006-09-14 2011-01-27 Shlomo Magdassi Organic nanoparticles obtained from microemulsions by solvent evaporation
EP1961412A1 (de) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Selbstmikroemulgierende Arzneimittelabgabesysteme
WO2008113177A1 (en) 2007-03-20 2008-09-25 Centre De Recherche Sur Les Biotechnologies Marines Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof
WO2008128292A1 (en) * 2007-04-20 2008-10-30 University Of South Australia Nanoparticle-coated capsule formulation for dermal drug delivery
US8778400B2 (en) * 2008-04-21 2014-07-15 University Of South Australia Nanoparticle-stabilized capsule formulation for treatment of inflammation
JP2014523911A (ja) * 2011-07-21 2014-09-18 黒▲龍▼江宝▲慶▼隆生物技▲術▼有限責任公司 イブプロフェン系化合物、その調製方法、使用および製剤

Also Published As

Publication number Publication date
EP3104840B8 (de) 2019-07-10
RU2016136430A3 (de) 2018-03-29
CN108472253A (zh) 2018-08-31
US20160354390A1 (en) 2016-12-08
US20150224121A1 (en) 2015-08-13
EP3104840A1 (de) 2016-12-21
CA2939562A1 (en) 2015-08-20
US9968621B2 (en) 2018-05-15
JP2017505349A (ja) 2017-02-16
EP3104840B1 (de) 2019-05-29
US9446056B2 (en) 2016-09-20
WO2015123272A1 (en) 2015-08-20
AU2015217309A1 (en) 2016-08-25
RU2016136430A (ru) 2018-03-15

Similar Documents

Publication Publication Date Title
CA2939562C (en) Parenteral compositions of celecoxib
Choudhury et al. Recent update on nanoemulgel as topical drug delivery system
US20220257510A1 (en) Compositions for Nanoemulsion Delivery Systems
KR102027613B1 (ko) 호르몬 함유 유화액
AU2007240317B2 (en) Stable emulsion formulations
Hippalgaonkar et al. Injectable lipid emulsions—advancements, opportunities and challenges
JP2022092040A (ja) アプレピタントのエマルジョン製剤
US20040096494A1 (en) Composition
JP5340954B2 (ja) 薬物含有脂肪乳剤およびその製造方法
RU2002111336A (ru) Дисперсии для изготовления композиций со слабо или плохо растворимыми агентами
CA3013288A1 (en) Emulsion comprising an nk-1 receptor antagonist
Tirnaksiz et al. Nanoemulsions as drug delivery systems
JP2008536919A (ja) 医薬組成物のエマルションの製造
Katiyar et al. Microemulsions: A novel drug carrier system
WO2018131620A1 (ja) 薬物含有脂肪乳剤およびその製造方法
Sabri et al. Comparison between conventional and supersaturable self-nanoemulsion loaded with nebivolol: preparation and in-vitro/ex-vivo evaluation
Mehta et al. Microemulsions as carriers for therapeutic molecules
Chauhan et al. Microemulsions: New vista in novel drug delivery system
Czerniel et al. A critical review of the novelties in the development of intravenous nanoemulsions
Atanase Nanoemulsions for drug delivery
WO2018182039A1 (ja) 薬物を保持した非水系組成物およびその製造方法
Shah et al. Nanoemulsions: Routes of Administration and Applications
RACHANA NON-STERODIAL ANTI-INFLAMMATORTY DRUG LOADED NANOEMLUGEL: DESIGN AND CHARACTERIZATION
Azeez et al. NANOEMULGEL AS A RECENT DRUG DELIVERY SYSTEM
Kesharwani Hira Choudhury, Bapi Gorain b, Manisha Pandey, Lipika Alok Chatterjee, Pinaki Sengupta c, Arindam Das b, Nagashekhara Molugulu, Prashant Kesharwani d

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200123

EEER Examination request

Effective date: 20200123

EEER Examination request

Effective date: 20200123

EEER Examination request

Effective date: 20200123

EEER Examination request

Effective date: 20200123